TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CD 20 positive, relapsed/refractory indolent lymphoma. (Regimens of prior chemotherapy are limited to 2; prior rituximab treatments up to 16 times are allowed.)~* Patients with measurable lesions (\> 1.5 cm).~* Patients who have not received any treatment for more than 4 weeks after completing previous therapies (6 months in the case of antibody therapies).~* ECOG performance status: 0 - 1~* Patients with adequately maintained organ functions.~Exclusion Criteria:~* Patients with infectious disease, serious complications, serious gastrointestinal symptoms, serious bleeding tendency, serious CNS symptoms, fever \</=38 °C, interstitial pneumonia or pulmonary fibrosis, active other malignancies, autoimmune hemolytic anemia or the history of the disease, or glaucoma.~* Patients who are positive for HBs antigen, HCV antibody, or HIV antibody.~* Patients who received G-CSF or transfusion within 1 week before the registration.~* Patients with the history of allergies to purine nucleoside analogue.~* Patients who experienced serious hypersensitivity or anaphylaxis to rituximab or mouse protein-derived products.~* Patients who had ever received prior therapy with fludarabine phosphate injection, pentostatin, cladribine, SH T 586, blood stem cell transplant, or monoclonal antibody therapy other than rituximab to NHL (including radioimmunotherapy).~* Patients who had progressive disease within 6 months of receiving therapy including rituximab.~* Women who are pregnant, of childbearing potential, or lactating.~* Patients who do not agree to practice contraception.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Auriculotherapy for Surgical Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is greater than 18 years of age~2. Subject is willing and able to provide informed consent~3. Subject is scheduled to undergo elective rotator cuff surgery~4. Subject has consented to an interscalene block~Exclusion Criteria:~1. Opioid dependence~2. Any subject diagnosed with a chronic pain condition which daily opioid use is needed~3. Anatomical malformation, which in the investigator's opinion may interfere with the placement of the nerve block~4. Raynaud's disease diagnosis~5. Vasculopathy~6. Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Auriculotherapy without nitrogen gas (Type: PLACEBO_COMPARATOR): Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
- Auriculotherapy with nitrogen gas (Type: ACTIVE_COMPARATOR): Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Internet-based Intervention for Hazardous Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Alcohol Use Disorders Identification Test (AUDIT) score from 6 (female) or 7 (male) to 12

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Web-based alcohol programme (Type: EXPERIMENTAL): Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~* 4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~* 2 weeks later for 6-week follow-up.
- Minimum information (Type: PLACEBO_COMPARATOR): Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable participants may be eligible to enroll within 10 days following hospital admission with high-risk acute coronary syndrome (either ST-elevation myocardial infarction \[STEMI\] or Non-STEMI or unstable angina)~* Participants not taking a statin must have an LDL-C of 125 mg/dl or less. Participants taking a statin must have an LDL-C of 100 mg/dl or less.~Exclusion Criteria:~* Pregnant or lactating woman, or intending to become pregnant~* Participant with active liver disease or persistent unexplained serum transaminase elevation~* History of alcohol or drug abuse~* History of sensitivity to statin or ezetimibe~* A participant for whom discontinuation of existing lipid lowering regimen poses an unacceptable risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ezetimibe/simvastatin (Type: EXPERIMENTAL): One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
- simvastatin (Type: ACTIVE_COMPARATOR): One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month~* Typically experiences moderate to severe migraine pain preceded by a mild pain phase~* Differentiate between mild migraine pain and other headache types~* Women of childbearing potential must be on adequate contraception~Exclusion Criteria:~* Pregnant and/or nursing mother~* History of cardiovascular disease~* Uncontrolled hypertension~* Basilar or Hemiplegic migraine~* History of stroke or transient ischemic attacks (TIA)~* History of epilepsy or treated with anti-epileptics within past 5 years~* Impaired hepatic or renal function~* History of gastrointestinal bleeding or ulceration~* Allergy or hypersensitivity to aspirin or any other NSAID~* Allergy or hypersensitivity to triptans~* Participated in an investigational drug trial in the previous 4 weeks

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must either be: postmenopausal, permanently surgically sterile, or perimenopausal or premenopausal and practicing a method of birth control until at least 1 month after the last dose of study drug.~* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).~Exclusion Criteria:~* Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, pulmonary or hepatic disease within the past 6 months that in the opinion of the investigator would adversely affect her participating in this study.~* History of any clinically significant sensitivity or allergy to any medication or food.~* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Venetoclax Sequence 1 (Type: EXPERIMENTAL): Participants will receive whole venetoclax, followed by crushed venetoclax, and completed with ground venetoclax for a 15 day period.
- Venetoclax Sequence 2 (Type: EXPERIMENTAL): Participants will receive crushed venetoclax, followed by ground venetoclax, and completed with whole venetoclax for a 15 day period.
- Venetoclax Sequence 3 (Type: EXPERIMENTAL): Participants will receive ground venetoclax, followed by whole venetoclax, and completed with crushed venetoclax for a 15 day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic migraine~* \>=15 headache days per month in past 30 days~* \>= 15 headache days, half of which need to be migraine headaches during the prospective baseline period~* MIDAS test score \>= 11 at Visit 1~* In generally good health~* If female, using birth control~* No abnormalities on neurological examination~Exclusion Criteria:~* Failed \> 2 adequate trials of migraine prevention medications~* Failed topiramate due to lack of effectiveness or adverse events~* Daily headaches of severe intensity during past 30 days~* Cluster, basilar, ophthalmoplegic, or hemiplegic migraines~* Migraines started after age 50~* Other pain greater than migraine pain~* Use of drugs to treat migraines for \> 4 days per week during the past month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese participants 20 years of age or older on the day of consent.~* Documented histological or cytological diagnosis of renal cell carcinoma (RCC) with a clear-cell component.~* Measurable disease per RECIST 1.1 as determined by the investigator.~* Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).~* For the most recently received VEGFR-targeting TKI the following criteria must apply:~  * Must have radiographically progressed during treatment, or been treated for at least 4 weeks and radiographically progressed within 6 months after the last dose.~Radiographic progression is defined as unequivocal progression of existing tumor lesions or developing new tumor lesions as assessed by the investigator on computerized tomography (CT) or magnetic resonance imaging (MRI) scans.~- The last dose must have been within 6 months before the first day of study drug administration (Week 1 Day 1).~* Recovery to baseline or ≤Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.~* Karnofsky Performance Status (KPS) score of ≥70%.~* Adequate organ and marrow function at Screening.~Exclusion Criteria:~* Prior treatment with everolimus, or any other specific or selective target of rapamycin complex 1/phosphoinositide 3-kinase/AKT inhibitor (eg, temsirolimus), or cabozantinib.~* Receipt of any type of small-molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before Week 1 Day 1.~* Receipt of any type of anticancer antibody (including investigational antibody) within 28 days before Week 1 Day 1.~* Radiation therapy for bone metastasis within 14 days, and/or any other external radiation therapy within 28 days before Week 1 Day 1. Systemic treatment with radionuclides within 42 days before Week 1 Day 1.~Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib 60 mg (Type: EXPERIMENTAL): Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, ages 18-45~* Body mass index (BMI) ≥18 and ≤32, and weight ≥ 110 lbs.~* Willing to use a non-hormonal method of contraception if at risk of pregnancy, OR have already undergone previous bilateral tubal ligation or hysterectomy~* Willing to refrain from use of alcohol and grapefruit juice from 48 hours prior until completion of each treatment period~Exclusion Criteria:~* Known or suspected pregnancy;~* Lactating women~* Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape~* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)~* Use of other contraceptive methods than study medication~* Smokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Ortho-Cyclen® (Type: ACTIVE_COMPARATOR): Ortho-Cyclen® is a comparator drug intervention
- AG200-15 (Type: EXPERIMENTAL): AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 2 month's history of nonmalignant pain, currently in stable pain control on opioid therapy.~* Good, very good or excellent pain control on current opioid therapy.~* Willing and able to use a telephone interactive voice response service.~Exclusion Criteria:~* Currently receiving daily morphine or oxycodone monotherapy.~* Scheduled for surgery of the disease site (eg, major joint replacement surgery), or any other major surgery, which would fall within the study period.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS (5, 10 or 20) (Type: EXPERIMENTAL): Buprenorphine transdermal patch
- Placebo to match BTDS (Type: PLACEBO_COMPARATOR): Placebo to match buprenorphine transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient age between 9-18 years~* Diagnosed obesity (BMI more than median plus two of standard deviation for age and sex according to WHO reference 2007)~Exclusion Criteria:~* Secondary obesity~* Thalassemia disease~* Renal and hepatic dysfunction~* Drugs: anticonvulsant, estrogen, thiazides, metformin, cholestyramine, methotrexate, fibrates, nicotinic acid~* Previous vitamin supplementation 1 month before study

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
- folic acid (Type: EXPERIMENTAL): Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Birthweight \<1500g~* Blood sugar \>/= 10mmol/L~* Clinician decision to start an insulin infusion~Exclusion Criteria:~* Infants who were moribund and not expected to survive

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with a clinical picture that assumes the diagnosis of erosive oral lichen planus (bilateral, more or less symmetrical erosive lesions with lacelike network of slightly raised gray white lesions (reticular pattern), and a histological findings that confirms the diagnosis (liquefaction degeneration of the basal cell layer with irregular-saw teeth like rete pegs.~Exclusion Criteria:~* Systemic disorders such as hematological diseases, severe cardiovascular diseases, treatment with any drugs that could cause Lichenoid reaction.~* Pregnancy or active breastfeeding~* Patients who had lesion/lesions with dysplasia~* Patients who received topical treatment for Oral Lichen planus in the last 2 weeks (Lee et al., 2013) or systemic treatment for OLP in the past 3 months.~* Platelet count \< 150,000/mm3; Hgb \< 11 g/dl.~* Immunosuppressed patients~* Patients receiving therapy with anticoagulants and use of non-steroidal anti-inflammatory drugs in the 5 days before taking the blood sample.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Platelet rich plasma (Type: EXPERIMENTAL): 0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
- Croticosteroids (Type: ACTIVE_COMPARATOR): 0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete